Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidene-2,4-thiazolidinediones

Radhe Shyam Bahare1*, Swastika Ganguly1, Kiattawee Choowongkomon2 and Supaporn Seetaha2

Abstract

Background: Structural modifications of thiazolidinediones at 3rd and 5th position have exhibited significant biological activities. In view of the facts, and based on in silico studies carried out on thiazolidine-2,4-diones as HIV-1- RT inhibitors, a novel series of 2,4-thiazolidinedione analogs have been designed and synthesized.

Methods: Title compounds were prepared by the reported method. Conformations of the structures were assigned on the basis of results of different spectral data. The assay of HIV-1 RT was done as reported by Silprasit et al. Antimicrobial activity was determined by two fold serial dilution method. Docking study was performed for the highest active compounds by using Glide 5.0.

Results: The newly synthesized compounds were evaluated for their HIV-1 RT inhibitory activity. Among the synthesized compounds, compound 24 showed significant HIV-1 RT inhibitory activity with 73% of inhibition with an IC50 value of 1.31 μM. Compound 10 showed highest activity against all the bacterial strains. A molecular modeling study was carried out in order to investigate the possible interactions of the highest active compounds 24, 10 and 4 with the non nucleoside inhibitory binding pocket (NNIBP) of RT, active site of GlcN-6-P synthase and cytochrome P450 14-a-sterol demethylase from Candida albicans (Candida P450DM) as the target receptors respectively using the Extra Precision (XP) mode of Glide software.

Conclusion: A series of novel substituted 2-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-(phenyl)propanamides (4-31) have been synthesized and evaluated for their HIV-1 RT inhibitory activity, antibacterial and antifungal activities. Some of the compounds have shown significant activity. Molecular docking studies showed very good interaction.

Keywords: Antibacterial, Antifungal, Docking, HIV-1 RT inhibitory activity, Thiazolidinediones, Synthesis

Background

The thiazolidinedione scaffold has been identified to play an essential role in medicinal chemistry [1,2]. Compounds containing the thiazolidinedione moiety have been found to exhibit a wide range of biological activities viz., antihyperglycemic [3], anti-inflammatory [4], antimalarial [5], antioxidant [6], antitumor [7], cytotoxic [8], antimicrobial [9], antiproliferative [10], MurD ligase inhibitor [11], monoamine oxidase B (MAO-B) inhibitor [12] neuroprotective [13], COX-2 inhibitor [14] and chemotherapeutic activities [15]. Recently, a novel series of thiazolidin-4-ones have emerged as selective NNRTIs [16]. However not much work has been reported on thiazolidine-2,4- diones as HIV-1-RT inhibitors.

HIV is the causative organism for AIDS and is continuously evolving and rapidly spreading throughout the world as a global infection. The HIV infection targets the monocytes expressing surface CD4 receptors and produces profound defects in cell-mediated immunity [17]. Overtime infection leads to severe depletion of CD4 T-lymphocytes (T-cells) resulting in opportunistic infections like tuberculosis (TB), fungal, viral, protozoal and neoplastic diseases and ultimately death [18].

Reverse transcription of the single-stranded (+) RNA genome into double-stranded DNA is an essential step in the HIV-1 replication life-cycle and requires the concerted
function of both the DNA polymerase and ribonuclease H (RNase H) active sites of HIV-1 reverse transcriptase (RT). Due to its essential role in HIV-1 replication, RT is a major target for anti-HIV drug development and two classes of inhibitors, (1) the nucleoside and nucleotide RT inhibitors and (2) the nonnucleoside RT inhibitors (NNRTIs) have been approved by the United States Food and Drug Administration (FDA) for the treatment of HIV-1 infection [19]. Though the NNRTIs are effective and generally well-tolerated in the majority of patients, treatment durability is limited by drug-related side effects and rapid emergence of resistance among HIV isolates. Thus, the therapeutic efficacy of NNRTIs is mainly restricted due to development of viral resistance to NNRTIs associated with mutations that include K103N, L100I and Y188L, and with the development of second generation NNRTIs, the search for a more suitable NNRTI, which blocks the replication of all existing resistant viral strains and retains potency for longer periods of time by modifying the existing drug classes or by incorporating appropriate substitutions in the newer chemical scaffolds, according to the pharmacologic requirements using multi-disciplinary approaches is the call of the day.

With the advent of AIDS and as a result of promiscuous use of drug therapy, antibacterial cytotoxins, steroids, or due to underlying disease or medical manipulation the normal defenses conferred by the microbial flora breaks down resulting in the prevalence of opportunistic bacterial and fungal infections. Bacterial diseases such as tuberculosis, typhus, plague, diphtheria, typhoid fever, cholera, dysentery and pneumonia have taken a high toll on humanity [20]. Along with this prevalence of multi-drug resistant microbial pathogens as an important and challenging therapeutic problem and therefore a search for newer antibacterial agents is the call of the day [21].

Opportunistic fungal infections have emerged as important causes of morbidity and mortality in immunocompromised patients and such infections include candidiasis, aspergillosis and mucormycosis [22]. A dramatic increase in invasive fungal infections over the past decade has been observed [23]. To overcome these problems, the development of new and safe antifungal agents with higher selectivity and lower toxicity is urgently required.

Glucosamine-6-phosphate synthase (GlcN-6-P synthase, L-glutamine:D-fructose-6-P amidotransferase), is a new target for antibacterials [24] and antifungals [25]. GlcN-6-P synthase catalyzes the first step in hexosamine metabolism, converting fructose 6-phosphate into glucosamine 6-phosphate (GlcN6P) in the presence of glutamine. The reaction catalyzed by GlcN-6-P synthase is irreversible, and is therefore considered as a committed step. The end product of the pathway, N-acetyl glucosamine, is an essential building block of bacterial and fungal cell walls.

Recent modeling studies report that azoles may be acting as antimicrobials by inhibition of GlcN-6-P synthase [24].

The fungal cell wall, a structure essential to fungi and lacking in mammalian cells, is an obvious target for antifungal agents. Its major macromolecular components are chitin, β-glucan, and mannanproteins [26]. In fungi, lanosterol 14-α-demethylase, a member of the cytochrome P450 superfamily, is an essential requirement for fungal viability. Azoles inhibit fungal cytochrome P-450 14-α-demethylase (DM) which is responsible for the conversion of lanosterol to ergosterol leading to the depletion of ergosterol in the fungal cell membrane [27-29]. Thus cytochrome P-450DM plays a key role in fungal sterol biosynthetic pathways, and this has been an important target for design of potent antifungals [30].

Structural modifications of thiazolidinediones at 3rd and 5th position have exhibited significant biological activities [31]. In view of the mentioned above facts, and based on in silico studies carried out on thiazolidine 2,4-diones as HIV-1- RT inhibitors [32], a novel series of 2,4-thiazolidinedione analogs have been designed based on the pharmacophoric model of NNRTIs 18 with the thiazolidinedione moiety attached to the propionamide moiety (−CH₂−CH₃−CO-NH−) constituting the “body (hydrophilic)” flanked by aryl rings (hydrophobic) linked to the 3rd and 5th position of the thiazolidinedione ring and to that of substituted aromatic amines as the “wings” to enhance the hydrophobicity of the molecules (Figure 1).

Herein we wish to report the synthesis of newer thiazolidine-2,4-diones, which have been evaluated for anti-HIV, antibacterial and antifungal activities. Binding mode analyses for the compounds with the highest HIV-1- RT inhibitory activity, antibacterial and antifungal activities have been carried out to understand the pharmacophoric features responsible for these activities.

**Experimental**

**Materials**

**Synthetic studies**

All reagents were purchased from commercial suppliers like Sigma Aldrich, Merck India Ltd., Himedia and Rankem chemicals. All reagents were GR or AR grade and were used without purification. The purity and homogeneity of the compounds were assessed by the TLC performed on Merck silica gel 60 F254 aluminium sheets using chloroform: methanol (9:1) as eluents. Iodine chamber and Shimadzu (UV-254) spectrometer were used for visualization of TLC spots. Ashless Whatmann No.1 filter paper was used for vacuum filtration. Melting points were determined on an SRS Opti-melting point automatic apparatus and were uncorrected. Elemental data of C, H and N were within ±0.4% of the theoretical value as determined by Perkin Elmer Model 240 analyzer. IR spectra (KBr disc/or pallets) were recorded on SHIAMADZU FT/IR 8400 and
were reported in cm⁻¹. H-NMR and ¹³C NMR spectra were respectively recorded at 400 and 100 MHz with BRUKER Advance Digital Spectrophotometer. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard, using DMSO-d₆. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard, using DMSO-d₆ and Mass spectra were recorded with a AZILANT Q-TOF Micromass LC-MS by using (ESI+).

Methods

General Procedure for the preparation of compounds (4–31)
Compounds 4–31 were synthesized as per the reported procedure [33]. Substituted 5-benzylidene-2,4-thiazolidinediones (2a-I) (0.01 mol) and the corresponding 3-chloro-N-phenylpropanamides (3a-I) (0.01 mol) were dissolved in 20 ml of acetonitrile. 0.02 mol of triethylamine was added dropwise to this solution with stirring. The reaction mixture was refluxed for 12 h, evaporated in rotary evaporator, cooled and poured into crushed ice and then basified with solid potassium carbonate. The resulting precipitate was filtered, washed with water (3 × 100 ml) and further washed with n-hexane (3 × 20 ml). The solid residue obtained was recrystallized from methanol to yield the desired compounds.

Thiazolidine-2,4-dione (1)
IR (KBr) cm⁻¹: 3132 (NH stretching), 1741, 1681 (C = O), ¹H-NMR (DMSO-d₆, 400 MHz): 12.50 (s; 1H; NH), 4.39 (2H, s, CH₂).

5-(benzylidene) thiazolidine-2,4-dione (2)
IR (KBr) cm⁻¹: 3146 (NH stretching), 3039 (Ar-CH stretching), 2789 (C-CH stretching), 1741, 1693 (C = O stretching).

2-chloro-N-phenylpropionamide (3)
IR (KBr) cm⁻¹: 3138 (NH stretching), 1689 (C = O stretching), 1303 (C-CN stretching), ¹H-NMR (DMSO-d₆, 400 MHz): 8.60 (s; 1H; NH), 8.12-7.24 (5H, m, Ar-H), 4.82 (q; 1H; CH-CH₃), 1.58 (s; 3H; CH-CH₃).

3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-3-hydroxyphenylpropanamide (4)
IR (KBr) cm⁻¹: 3353 (OH stretching), 3153 (NH stretching), 1741, 1676, 1648 (C = O stretching), 1329 (C-N aliphatic stretching), ¹H-NMR (DMSO-d₆, 400 MHz): 10.39 (s; 1H; 3′′OH), 9.83 (s; 1H; NH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 9H; Ar-H), 3.93 (t; 2H; N-CH₂-CH₂-CO), 2.66 (t; 2H; N-CH₂-CH₂-CO), ¹³C NMR (DMSO-d₆): 167.0, 166.0, 164.5 (C = O), 149.1 (C, Ar), 140.0 (C, Ar), 136.0 (=CH-), 135.1 (C, Ar), 130.0 (CH, Ar), 129.2 (2C, CH, Ar), 128.5 (2C, CH, Ar), 128.1, 124.3 (CH, Ar), 121.5 (C-5 TZD), 119.8 (CH, Ar), 117.1 (CH, Ar), 41.5 (CH₂-CH₂), 31.2 (CH₂-CH₂), MS (ESI+) m/z 369.0 (M+).

3-(5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)-N-phenylpropionamide (5)
IR (KBr) cm⁻¹: 3363 (OH stretching), 3153 (NH stretching), 1741, 1676, 1648 (C = O stretching), 1329 (C-N aliphatic stretching), ¹H-NMR (DMSO-d₆, 400 MHz): 10.39 (s; 1H; 3′′OH), 9.83 (s; 1H; NH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 9H; Ar-H), 3.93 (t; 2H; N-CH₂-CH₂-CO), 2.66 (t; 2H; N-CH₂-CH₂-CO), ¹³C NMR (DMSO-d₆): 167.0, 166.0, 164.5 (C = O), 149.1 (C, Ar), 140.0 (C, Ar), 136.0 (=CH-), 135.1 (C, Ar), 130.0 (CH, Ar), 129.2 (2C, CH, Ar), 128.5 (2C, CH, Ar), 128.1, 124.3 (CH, Ar), 121.5 (C-5 TZD), 119.8 (CH, Ar), 117.1 (CH, Ar), 41.5 (CH₂-CH₂), 31.2 (CH₂-CH₂), MS (ESI+) m/z 369.0 (M+).

Figure 1 Pharmacophoric model of 2,4-thiazolidinedione analogs.
N-CH$_2$-CH$_2$-CO), 2.63 (t; 2H; N-CH$_2$-CH$_2$-CO), MS (ESI+) m/z 369.0 (M+).
3-(5-(2-fluorobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-phenylpropanamide (6)
IR (KBr) cm$^{-1}$: 3313 (NH stretching), 3051, 2929 (Ar-CH stretching), 1753, 1687, 1661 (C = O stretching), 1136 (C-F stretching), $^1$H-NMR (DMSO-d$_6$, 400 MHz): 10.03 (s; 1H; NH), 7.88 (s; 1H; C = CH), 7.58-6.98 (m; 9H; Ar-H), 3.93 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.66 (t; 2H; N-CH$_2$-CH$_2$-CO), MS (ESI+) m/z 371.0 (M+).
3-(5-(3-benzylenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(3-hydroxyphenyl)propanamide (7)
IR (KBr) cm$^{-1}$: 3525, 3416 (OH stretching), 3232 (NH stretching), 3053, 2947 (Ar-CH stretching), 1722, 1664, 1652 (C = O stretching), $^1$H-NMR (DMSO-d$_6$, 400 MHz): 10.00 (s;1H; NH), 9.79 (s; 1H; 3’OH), 9.78 (s; 1H; 3’OH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 8H; Ar-H), 3.90 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.63 (t; 2H; N-CH$_2$-CH$_2$-CO), MS (ESI+) m/z 385.1 (M+).
3-(5-benzylenzylidene)-2,4-dioxothiazolidin-3-yl)-N- (2-chlorophenyl)propanamide (8)
IR (KBr) cm$^{-1}$: 3306 (NH stretching), 1743, 1683, 1649 (C = O stretching), 821 (Cl-Cl stretching), $^1$H-NMR (DMSO-d$_6$, 400 MHz): 10.05 (s; 1H; NH), 8.06 (s; 1H; C = CH), 8.02-7.20 (m; 7H; Ar-H), 3.33 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.66 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.30 (s; 6H; 4’-CH$_3$), 2.24 (s; 3H; 4’-CH$_3$), MS (ESI+) m/z 395.2 (M+).
3-(5-(2,4-dimethylbenzylidene)-2,4-dioxothiazolidin-3-yl)-N-p-tolyllpropanamide (9)
IR (KBr) cm$^{-1}$: 3386 (NH stretching), 2935, 2852 (C-CH$_3$ stretching), 1747, 1703, 1685 (C = O stretching), $^1$H-NMR (DMSO-d$_6$, 400 MHz): 10.05 (s; 1H; NH), 8.06 (s; 1H; C = CH), 8.02-7.20 (m; 7H; Ar-H), 3.33 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.66 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.30 (s; 6H; 4’-CH$_3$), 2.24 (s; 3H; 4’-CH$_3$), MS (ESI+) m/z 395.2 (M+).
3-(5-(2,4-dimethylbenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-hydroxyphenyl)propanamide (10)
IR (KBr) cm$^{-1}$: 3389 (OH stretching), 3198 (NH stretching), 2995, 2885 (C-CH$_3$ stretching) 1668, 1646, 1640 (C = O stretching), $^1$H-NMR (DMSO-d$_6$, 400 MHz): 10.20 (s; 1H; OH), 10.11 (s; 1H; NH), 7.90 (s; 1H; C = CH), 7.61-7.29 (m; 7H; Ar-H), 3.93 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.70 (t; 2H; CH$_3$), 2.45 (s; 3H; 2’- CH$_3$), 2.24 (s; 3H; 5’-CH$_3$), $^{13}$C NMR(δ) DMSO-d$_6$: 166.7, 166.4, 164.5 (C = O), 148.1 (C, Ar), 135.8, 134.7, 133.0 (C, Ar), 132.8 (-CH$_2$-), 130.2, 129.0, 127.2, 125.4 (CH, Ar), 122.2 (CH, Ar), 121.5 (C-S TZD), 120.2, 119.2 (CH, Ar), 116.0 (CH, Ar), 121.0, 119.4 (C-CH$_3$), 41.5 (CH$_2$-CH$_3$), 31.2 (CH$_2$-CH$_3$), MS (ESI+) m/z 397.2 (M+).
1683,1656 (C = O stretching), $^1$H-NMR (DMSO-$d_6$, 400 MHz): 14.09 (s; 1H; 2′OH), 10.09 (s; 1H; 3′OH), 9.50 (s; 1H; 4′OH), 9.31 (s;1H; NH), 8.06(s;1H; C = CH), 8.04 -7.20 (m; 6H; Ar-H), 3.84 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.39 (s; 3H; 4′CH$_3$), 2.33 (t; 2H; N-CH$_2$-CH$_2$-CO), MS (ESI+) m/z 415.3 (M$^+$).

3-((3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-chloro-5-methylphenyl)-propanamide (18)

IR (KBr) cm$^{-1}$: 3308 (OH stretching), 3232 (NH stretching), 3057, 2960 (Ar-CH stretching), 2924, 2854 (C=CH$_3$ stretching), 1691,1656, 1646 (C = O stretching), 752 (C-Cl stretching), 514 (N=O stretching), 1681, 1647, 1638 (C = O stretching), 1451, 1421, 1360 (C, Ar), 1307, 1290, 1258 (CH, Ar), 1243 (C, Ar), 1236, 1230 (CH, Ar), 1125 (C-5 TZD), 1101, 1093 (CH, Ar), 41.5 (CH$_2$-CH$_2$), 31.2 (CH$_2$-CH$_2$), MS (ESI+) m/z 432.8 (M$^+$).

IR (KBr) cm$^{-1}$: 3306 (NH stretching), 3039 (Ar-CH stretching), 2916, 2858 (C=CH$_3$ stretching), 1681, 1651,1644 (C = O stretching), 742 (C=C stretching) $^1$H-NMR (DMSO-$d_6$, 400 MHz): 10.02 (s; 1H; NH), 7.88 (s; 1H; C = CH), 7.58-7.23 (m; 7H; Ar-H), 3.99 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.60 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.28 (s; 3H; 4′CH$_3$), 2.24 (s; 3H; 4′CH$_3$).

3-((3,5-dimethylbenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-chloro-4-methylphenyl)-propanamide (20)

IR (KBr) cm$^{-1}$: 3267 (NH stretching), 3039 (Ar-CH stretching), 2916, 2858 (C=CH$_3$ stretching), 1681, 1651,1644 (C = O stretching), 742 (C=C stretching) $^1$H-NMR (DMSO-$d_6$, 400 MHz): 10.07 (s; 1H; NH), 8.04 (s; 1H; C = CH), 7.84-7.20 (m; 6H; Ar-H), 3.92 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.66 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.30 (s; 6H; CH$_3$), 2.24 (s; 3H; 4′CH$_3$).

3-((3-chloro-4,5-dimethylbenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-chloro-4-methylphenyl)-propanamide (21)

IR (KBr) cm$^{-1}$: 3145 (NH stretching), 1685, 1657, 1644 (C = O stretching), 1311 (C=O2 stretching), 776 (C=C stretching) $^1$H-NMR (DMSO-$d_6$, 400 MHz): 10.39 (s; 1H; NH), 8.01(s;1H; =CH), 7.91-7.32 (m; 8H; Ar-H), 3.91 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.72 (t; 2H; N-CH$_2$-CH$_2$-CO), MS (ESI+) m/z 432.8 (M$^+$).

3-((2-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-nitrophenyl)propanamide (22)

IR (KBr) cm$^{-1}$: 3237 (NH stretching), 1739, 1670, 1652 (C = O stretching), 1451, 1421, 1360 (C, Ar), 1307, 1095, 1037, (CH, Ar), 41.5 (CH$_2$-CH$_2$), 31.2 (CH$_2$-CH$_2$), 20.7 (CH$_3$), MS (ESI+) m/z 436.2 (M$^+$).

3-((4-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-chloro-4-methylphenyl)propanamide (23)

IR (KBr) cm$^{-1}$: 3306 (NH stretching), 1743, 1693, 1612 (C = O stretching), 1342 (C=O2 stretching), 754 (C=C stretching) $^1$H-NMR (DMSO-$d_6$, 400 MHz): 10.00 (s; 1H; NH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 8H; Ar-H), 3.90 (t; 2H; N-CH$_2$-CH$_2$-CO), 2.63 (t; 2H; N-CH$_2$-CH$_2$-CO).

3-((4-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(2-nitrophenyl)propanamide (24)

IR (KBr) cm$^{-1}$: 3312 (NH stretching), 2975, 2931 (Ar-CH stretching), 2896 (C=CH$_3$ stretching), 2546 (SH stretching), 1688, 1647, 1638 (C = O stretching), $^1$H-NMR (DMSO-$d_6$, 400 MHz): 13.96 (s; 1H; 2′OH), 10.09 (s; 1H; 3′OH), 9.50 (s; 1H; 4′OH), 9.31 (s;1H; NH), 8.01 (s;1H; C = CH), 7.90-7.18 (m; 6H; Ar-H), 3.84 (t; 2H; N-CH$_2$-CH$_2$-CO), 3.49 (s; 1H; 2′SH), 2.30 (t; 2H; N-CH$_2$-CH$_2$-CO), 13CNMR(δ)DMSO-d$_6$: 167.2, 165.5, 164.5 (C = O), 148.2, 145.2, 142.1, 136.0 (C, Ar), 136.1 (=CH-), 130.2, 129.0, 125.8 (CH, Ar), 124.3 (C, Ar), 123.6, 123.0 (CH, Ar), 112.5 (C-5 TZD), 110.1, 109.3 (CH, Ar), 41.5 (CH$_2$-CH$_2$), 31.2 (CH$_2$-CH$_2$), MS (ESI+) m/z 432.8 (M$^+$).
IR (KBr) cm\(^{-1}\): 3411 (OH stretching), 3372 (NH stretching), 1688, 1669, 1646 (C = O stretching), 668 (C-Br stretching), 1\(^{1}\)H-NMR (DMSO-\(d_6\), 400 MHz): 9.97 (s; 1H; 2\(^{′}\)OH), 9.84 (s; 1H; NH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 8H; Ar-H), 3.91 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 2.64 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 1\(^{3}\)CNMR(\(d\)) DMSO-\(d_6\): 167.2, 165.2, 164.5 (C = O), 148.9, 138.1, 135.3 (=CH-), 135.1 (C, Ar), 132.3, 130.1, 128.1, 127.1, 127.0 (CH, Ar), 121.5 (C-5 TZD), 113.0, (C, Ar), 112.9, 109.5, 104.8 (CH, Ar), 41.5 (CH\(_2\)-CH\(_2\)), 31.2 (CH\(_2\)-CH\(_2\)), MS (ESI+) m/z 448.0.

3-(5-(2-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(3-hydroxyphenyl)propanamide (29)

IR (KBr) cm\(^{-1}\): 3207 (NH stretching), 1710, 1685, 1658 (C = O stretching), 1319 (C=NO\(_2\) stretching), 750 (C-Br stretching), 1\(^{1}\)H-NMR (DMSO-\(d_6\), 400 MHz): 9.84 (s; 1H; OH), 9.61 (s; 1H; NH), 7.81 (s; 1H; C = CH), 7.52-6.86 (m; 8H; Ar-H), 3.91 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 2.64 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), MS (ESI+) m/z 480.2 (M+).

3-(5-(3-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(4-nitrophenyl)propanamide (30)

IR (KBr) cm\(^{-1}\): 3207 (NH stretching), 1710, 1685, 1658 (C = O stretching), 1319 (C=NO\(_2\) stretching), 750 (C-Br stretching), 1\(^{1}\)H-NMR (DMSO-\(d_6\), 400 MHz): 9.73 (s; 1H; NH), 8.12 (s; 1H; C = CH), 8.09 -7.53 (m; 8H; Ar-H), 3.83 (t(t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 2.20 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO).

3-(5-(3-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-N-(4-chloro-3-methylphenyl) propanamide (31)

IR (KBr) cm\(^{-1}\): 3284 (NH stretching), 3014, 2922 (C-CH\(_3\) stretching) 1702, 1676, 1652 (C = O stretching), 779 (C-Br Stretching), 675 (C-Br Stretching), 1\(^{1}\)H-NMR (DMSO-\(d_6\), 400 MHz): 10.11 (s; 1H; NH), 7.90 (s; 1H; C = CH), 7.61 -7.29 (m; 7H; Ar-H), 3.90 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 2.64 (t; 2H; N-CH\(_2\)-CH\(_2\)-CO), 2.45 (s; 3H; 3\(^{′}\) CH\(_3\)), MS (ESI+) m/z 480.2 (M+).

**Biological assays**

The standard strains were procured from Institute of Microbial Technology, Chandigarh and National Chemical Laboratory, Pune. Antimicrobial activity was determined by two fold serial dilution method [34] in duplicates against pathogenic microorganisms Gram-positive bacteria: *Staphylococcus aureus* (NCIM 2122), *Bacillus subtilis* (MTCC 121), Gram-negative bacteria: *Escherichia coli* (MTCC118), *Pseudomonas aeruginosa* (MTCC 647), *Salmonella typhi* (NCIM 2501), *Klebsiella pneumonia* (MTCC 3384) and fungus *Candida albicans* (MTCC 227), *Aspergillus niger* (NCIM 1056). Test compounds were dissolved in 10% DMSO, to produce a 2000 μg/mL stock solution. These test tubes were serially diluted to give a concentration of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, and 0.78 μg/mL. MHB (Mueller-Hinton Broth) was used for bacteria and SDB (Sabouraud Dextrose Broth) was used for fungus. The cell density of each inoculum was adjusted in sterile water of a 0.5 McFarland standard. A final concentration of ~10\(^{7}\) CFU/mL and ~10\(^{6}\) CFU/mL was obtained for bacteria and fungus, respectively. Microbial inocula were added to the twofold diluted samples. The test tubes were incubated 18–24 h at 37°C ±1°C for bacteria and 2–5 days at 25°C ±1°C for fungus. Ciprofloxacin and fluconazole were used as standard drugs. The highest dilution of the test compound that completely inhibited the growth of test organism was considered as the MIC value of the test compound and was expressed in μg/mL.

**HIV-1 reverse transcriptase inhibition assay**

The assay of HIV-1 RT was done as reported by Silprasit et al. [35]. All reagents used were provided in the EnzChek\textsuperscript{®} Reverse Transcriptase Assay Kit (Molecular Probes, USA). A mixture of 5 μL of 1 mg/mL 350 bases-poly(rA) ribonucleotide template and 5 μL of 50 μg/mL oligo d(T)\(_{16}\) primer in a nuclease-free microcentrifuge tube were incubated at room temperature (25°C) for 1 hour to allow the primer/template annealing. The primer/template was prepared by 200-fold dilution in polymerization buffer. The primer/template was aliquoted and kept at −20°C until used. Five microliter of 8 μM stock purified HIV-1 reverse transcriptase was aliquoted and kept at −80°C until used. The working enzyme was diluted to 400 nM with 50 mM Tris–HCl, 20% glycerol, 2 mM DTT, pH 7.5.

The assays were performed in a total volume 15 μL of the polymerization reaction. The reaction containing 3 μL of 400 nM recombinant HIV-1 RT (the final concentration is 80 nM), 2 μL of TE buffer (10 mM Tris–HCl at pH 7.5) were added and gently mixed on ice prior. The polymerization reaction was initiated by the addition of 10 μL of the primer/template and incubated at room temperature for 30 minutes. After the reactions reached the desired incubation time, 5 μL of 0.2 M EDTA was added to stop the polymerization reaction (RTControl). The blank reaction was prepared by mixing 5 μL of 0.2 M EDTA with enzyme before adding primer/template (RTBlank). After termination of the reactions, the plate was gently shaken and incubated at room temperature for 3 min to allow the formation of a stable heteroduplex DNA/RNA complex, followed by addition of 180 μL of PicoGreen reagent diluted 700-fold with TE buffer for each well, making the final volume 200 μL and incubation at room temperature in the dark for 3 min, during which PicoGreen binds to double-stranded DNA and RNA-DNA hybrids, was followed by measurement of fluorescence with a fluorometer (excitation 485 nm; emission 535 nm).

To test the inhibition efficiency of the compounds, all the compounds were dissolved in dimethyl sulfoxide (DMSO) to make a 20 mM stock solution. Ten micromolar working solution of each inhibitor was further diluted by 10 μM
Tris–HCl, pH 7.5 containing 50% DMSO. Two microliter of each inhibitor and 3 μL of 400 nM recombinant HIV-1 RT were added and gently mixed on ice prior. The reaction was initiated by the addition of 10 μL of the primer/template and incubated at room temperature for 30 minutes. After the reactions reached the desired incubation time, 5 μL of 0.2 M EDTA was added to stop the polymerization reaction. The relative inhibitory effect of HIV-1 RT activity was compared by using percent inhibition, which was calculated via the following eq (1):

\[
\% \text{ relative inhibition} = \left( \frac{\text{RT}_{\text{Control}} - \text{RT}_{\text{Background}}}{\text{RT}_{\text{Sample}} - \text{RT}_{\text{Background}}} \right) \times 100
\]

Determination of the IC\textsubscript{50} inhibition value

Determination of the IC\textsubscript{50} was done by adding 2 μL of each two-fold serial dilution of inhibitors. Two microliters of each test compound was diluted serially 2-fold. Then, 2 μL of 30 ng/μL purified HIV-1 RT was added and mixed. A volume of 4 μL of the template/primer polymerization buffer was added into each well. The mixtures were incubated at 37°C for 10 min. The reactions were stopped with 5 μL of 200 mM EDTA and immediately incubated on ice for 30 min. The activity was determined by the PicoGreen–fluorometric method. The reaction was repeated three times and were determined using Graph pad Prism4 version with a non-linear regression model.

Computational method with Glide 5.0

Docking study was performed for the highest active compounds by using Glide 5.0 (Schrodinger) [36] installed in a single machine running on a 3.4 GHz Pentium 4 processor with 1GB RAM and 160 GB Hard Disk with Red Hat Linux Enterprise version 5.0 as the operating system.

Protein structure preparation

The X-ray crystallographic structure of (PDB code 1RT2, 2VF5 and 1EA1) was obtained from Brookhaven Protein Data Bank (RCSB) [37]. All water molecules were removed from the complex, and the protein was minimized using the protein preparation wizard. Partial atomic charges were assigned according to the OPLS-AA force field. A radius of 10 Å was selected for active site cavity during receptor grid generation for 2VF5. After assigning charge and protonation state finally refinement (energy minimization) was done using MM3 force field runs.

Crystallographic structure of the complex between cytochrome P450 14-R-sterol demethylase from Mycobacteria (Mycobacterium P450DM) and fluconazole was present in the Protein Data Bank with the ID 1EA1 [38]. The high homology existing between these two analogous enzymes [39] suggested building a simple model consisting of the crystallographic structure of the complex 1EA1 in which the residues that are arranged in a range of 7 Å from fluconazole, were substituted with those of Candida P450DM according to reported method [33]. Only 12 substitutions were made by replacement of the residues Pro77, Phe78, Met79, Arg96, Met99, Leu100, Phe255, Ala256, His258, Ile322, Ile323 and Leu324 by Lys77, His78, Leu79, Leu96, Lys99, Phe100, Met255, Gly256, Gln258, His322, Ser323 and Ile324, which were thought to be necessary for the ligand-receptor interaction. The complex between the chimeric enzyme thus obtained and was then minimized.

Ligand structure preparation

All the compounds used in the docking study with Glide were built within maestro by using build module of Schrodinger Suite 2008. These structures were geometry optimized by using the Optimized Potentials for Liquid Simulations-2005 (OPLS_2005) force field with the steepest descent protocol followed by truncated Newton conjugate gradient protocol. Partial atomic charges were computed using the OPLS_2005 force field.

Docking protocol and their validation

All docking calculations were then performed using the “Extra Precision” (XP) mode of Glide Program 5.0. A grid was prepared with the center defined by the co-crystallized ligand. During the docking process, initially Glide performed a complete systematic search of the conformational, orientational and positional space of the docked ligand and eliminated unwanted conformations using scoring followed by energy optimization. Finally the conformations were further refined via Monte Carlo sampling of pose conformation. Predicting the binding affinity and rank-ordering ligands in database screens was implemented by modified and expanded version of the Glide scoring function. The most suitable method of evaluating the accuracy of a docking procedure is to determine how closely the lowest energy pose predicted by the scoring function resembles an experimental binding mode as determined by X-ray crystallography. Docking validation was performed with an obtained RMSD value of 0.370 Å for 1RT2, 1.674 Å for 2VF5 and 2.094 Å for 1EA1 ensuring precision and reproducibility of the docking process.

Results and discussion

Chemistry

An attempt has been made to incorporate aryl groups in the 3rd and 5th position of the thiazolidinedione structure according to Scheme 1. In the first step the cyclization of
chloroacetic acid was carried out with equimolar amounts of thiourea and chloroacetic acid, and then hydrolysed with 2 N HCl to afford 2,4-thiazolidinedione (1). Knoevenagel condensation of 2,4-thiazolidinedione and appropriate aryl aldehydes was carried out in ethanol under reflux conditions containing catalytic amount of piperidine, as base, to form the corresponding substituted 5-benzylidene-2,4-thiazolidinediones (2) [33]. N-chloro-3-(phenylamino)propanamides (3) were prepared by the reported method [40]. Substituted N-chloro-3-(phenylamino)propanamides (3) were thus prepared by reacting appropriate aryl amines with 3-chloropropionyl chloride in the presence of glacial acetic acid in cold condition. The substituted 5-benzylidene-2,4-thiazolidinediones (2) were condensed with substituted N-chloro-3-(phenylamino)propanamides (3) in the presence of triethylamine using acetonitrile as the solvent to get substituted 3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-phenylpropanamides 4–31.

The physical data are given in Table 1. FTIR, 1H-NMR and mass spectral data for all the synthesized compounds are given in the above experimental protocols. The IR spectrum of all the final compounds exhibited very similar features and showed the expected bands for the characteristic groups present in the compounds such as N-H stretching in the range of 3390–3136 cm⁻¹ and C = O stretching in the range of 1750–1645 cm⁻¹ to confirm the presence of thiazolidinedione ring system. 1H NMR showed a characteristic singlet peak assigned to a δ value in the range of 10.39–9.31 thus confirming the presence of NH proton of thiazolidinedione scaffold in compounds 4–31. The methylenic (C=CH) protons of compounds 4–31 were seen as a singlet between 8.12-7.80 δppm while aromatic protons appeared as multiple peaks within the range 8.04-6.20 δppm. Characteristic triplet of 2 protons was assigned at δ ranging 3.99-2.66 to the methylenic protons of N-CH₂-CH₂-CO. Similarly; a triplet of 2 protons was assigned to the methylenic protons of N-CH₂-CH₂-CO observed at δ ranging 2.76-2.20 for all the compounds 4–31. The 13C NMR depicted the peaks of thiazolidine-2,4-dione (TZD) nucleus within the range δ 166.2-164.3 (thiazolidine-
Table 1 Physical data of synthesized compounds (4–31)

| Comp. no. | R        | R'       | Mol. formula    | Yield (%) | M.P. (°C) | M.W.  | Elemental analysis calculated/found |
|-----------|----------|----------|-----------------|-----------|-----------|-------|-------------------------------------|
|           |          |          |                 |           |           |       | C   | H  | N   |
| 4         | H        | 3-OH     | C_{19}H_{16}N_{2}O_{5}S | 57        | 289       | 368.41| 61.94 | 4.38 | 7.60 |
| 5         | 3-OH     | H        | C_{19}H_{16}N_{2}O_{5}S | 55        | 243       | 368.41| 61.94 | 4.38 | 7.60 |
| 6         | 2-F      | H        | C_{19}H_{14}ClFN_{2}O_{3}S | 52        | 186       | 370.40| 56.37 | 3.49 | 6.92 |
| 6         | 2-F      | H        | C_{19}H_{14}ClFN_{2}O_{3}S | 52        | 186       | 370.40| 56.37 | 3.49 | 6.92 |
| 7         | 3-OH     | 3-OH     | C_{19}H_{16}N_{2}O_{5}S | 58        | 129       | 348.41| 59.37 | 4.20 | 7.29 |
| 8         | H        | Cl       | C_{19}H_{13}N_{2}O_{3}S | 55        | 183       | 386.85| 58.99 | 3.91 | 7.24 |
| 9         | 2,4-CH_{3}| 4-CH_{3} | C_{20}H_{12}N_{2}O_{5}S | 62        | 284       | 394.49| 66.98 | 5.62 | 7.10 |
| 10        | 2,5-CH_{3}| 2-OH    | C_{21}H_{20}N_{2}O_{4}S | 64        | 302       | 396.46| 63.62 | 5.08 | 7.07 |
| 11        | 2,4-CH_{3}| 2-OH    | C_{21}H_{20}N_{2}O_{4}S | 58        | 189       | 396.46| 63.62 | 5.08 | 7.07 |
| 12        | 3,5-CH_{3}| 2-OH    | C_{21}H_{20}N_{2}O_{4}S | 56        | 293       | 396.46| 63.62 | 5.08 | 7.07 |
| 13        | 2,4-OH   | 2-OH    | C_{19}H_{16}N_{2}O_{5}S | 52        | 243       | 400.41| 56.99 | 4.03 | 7.00 |
| 14        | H        | 2-Cl, 4-CH_{3}| C_{20}H_{13}ClN_{2}O_{3}S | 58        | 109       | 400.88| 59.92 | 4.27 | 6.99 |
| 15        | H        | 4-Cl, 3-CH_{3}| C_{20}H_{13}ClN_{2}O_{3}S | 56        | 113       | 400.88| 59.92 | 4.27 | 6.99 |
| 16        | 2-Cl     | 4-CH_{3} | C_{20}H_{13}ClN_{2}O_{3}S | 68        | 279       | 400.88| 59.92 | 4.27 | 6.99 |
| 17        | 2,3-4-OH | 4-CH_{3} | C_{20}H_{18}N_{2}O_{5}S | 44        | 253       | 414.43| 57.96 | 4.38 | 6.76 |
| 18        | 3-OH     | 2-Cl,5-CH_{3}| C_{20}H_{13}ClN_{2}O_{4}S | 66        | 173       | 416.88| 57.62 | 4.11 | 6.72 |
| 19        | 2-F      | 2-Cl,4-CH_{3}| C_{20}H_{10}ClFN_{2}O_{3}S | 60        | 175       | 418.87| 57.35 | 3.85 | 6.69 |
| 20        | 3,5-CH_{3}| 2-Cl,4-CH_{3}| C_{21}H_{12}ClN_{2}O_{3}S | 55        | 308       | 428.03| 61.60 | 4.93 | 6.53 |
| 21        | 2-Cl     | 4-NO_{2} | C_{19}H_{14}ClN_{2}O_{3}S | 58        | 282       | 431.85| 52.84 | 3.27 | 9.73 |
| 22        | 2-Cl     | 2-NO_{2} | C_{19}H_{14}ClN_{2}O_{3}S | 66        | 174       | 431.85| 52.84 | 3.27 | 9.73 |
| 23        | 4-Cl     | 2-NO_{2} | C_{19}H_{14}ClN_{2}O_{3}S | 52        | 240       | 431.85| 52.84 | 3.27 | 9.73 |
2,4-dione -C = O). $^{13}$C NMR spectrum showed signals for thiazolidine-2,4-dione-C-5 atom at δ 121.5.

### Biological activity

All the synthesized compounds were also evaluated for in vitro antibacterial activity against Gram-positive bacteria: *Staphylococcus aureus* (NCIM 2122), *Bacillus subtilis* (MTCC 121), Gram-negative bacteria: *Escherichia coli* (MTCC118), *Pseudomonas aeruginosa* (MTCC 647), *Salmonella typhi* (NCIM 2501), *Klebsiella pneumonia* (MTCC 3384) and fungus *Candida albicans* (MTCC 227), *Aspergillus niger* (NCIM 1056), by using the two-fold serial dilution technique and the results are summarized in Table 2. Ciprofloxacin was used as the standard for antibacterial activity and fluconazole was used as the standard for antifungal activity.

Compound 10 showed highest activity against all the bacterial strains. Compound 4 and 10 showed highest activity against *E. coli* while compound 24 exhibited moderate activity against the same bacterial strain while exhibited weak activity against all the other bacterial strains. Compound 5 and 7 exhibited highest activity against *B. subtilis* and *K. pneumoniae* respectively while compound 17 exhibited moderate activity against all the three bacterial strains *B. subtilis, E. coli* and *S. typhi*. Compound 8 exhibited moderate activity against *S. aureus*. However, all these compounds exhibited activity less than that of standard drug ciprofloxacin. Rest of the compounds showed mild to moderate activity against all other bacterial strains.

Compound 4 exhibited excellent activity against the fungal strains *C. albicans* and *A. niger*. In fact, the activity was higher than that of standard fluconazole. Compound 7, 8, 15, 19, 21, 24 and 27 also exhibited very high activity against both the fungal strains comparable to the standard drug. Compounds 5, 10, 11, 18 and 28 exhibited significant activity against *C. albicans* while showing moderate activity against *A. niger*. All other compounds showed moderate to weak antifungal activity against both the fungal strains.

The introduction of phenyl groups substituted at different positions with electronegative groups such as chloro, hydroxyl and nitro enhances the antimicrobial activity, particularly evident in case of antifungal activity. However, the introduction of one methyl group does not have much influence in the increase or decrease of antifungal activity as in case of compounds 19 and 27. The introduction of two methyl groups in the phenyl ring directly substituted at the 5th position of the thiazolidine – 2,4-dione nucleus results in slight decrease in the antifungal activity but increases antibacterial activity as is evident from the activity of compound 10.

The newly synthesized compounds were evaluated for their HIV-1 RT inhibitory activity. Percentage of inhibition has given in Table 3. Among the synthesized compounds, compound 24 showed significant HIV-1 RT inhibitory activity with 73% of inhibition with an IC$_{50}$ value of 1.31 μM. Compound 23 also showed 58% inhibition, however its IC$_{50}$ value was negligible. Rest of compounds showed weak activity.

From the results of HIV-1 RT inhibitory activity, it is evident that compound 24 with hydroxyl groups substituted at 2, 3 and 4 positions of the phenyl ring attached at the 5$^{th}$ position of the thiazolidinedione ring with a linker
group CH₂CH₂CONH at the N-3 position linked to a second phenyl ring substituted with a 2-mercapto group positively influenced the activity.

According to the above obtained data, we found that compounds 4–31 exhibited promising antimicrobial activities. In case of HIV-1-RT inhibitory activity, only compound 24 was found to be significantly active while the others exhibited weak non-nucleoside reverse transcriptase activity.

### Table 2 In vitro antibacterial and antifungal activity data of test compounds: 4–31

| Comp. code | S. a | B. s | E. c | P. a | S. t | K. P | C. a | A. n | Minimum inhibitory concentration MIC (μg/mL) |
|------------|-----|-----|-----|------|-----|-----|-----|-----|---------------------------------------------|
| 4          | 50  | 25  | 6.25| 50   | 50  | 50  | 3.12| 6.25|                                             |
| 5          | 50  | 6.25| 25  | 25   | 50  | 50  | 12.5| 25  |                                             |
| 6          | 100 | 50  | 50  | 100  | 50  | 25  | 50  | 6.25|                                             |
| 7          | 25  | 50  | 50  | 25   | 25  | 6.25| 6.25| 12.5|                                             |
| 8          | 12.5| 25  | 25  | 50   | 25  | 50  | 12.5| 25  |                                             |
| 9          | 100 | 100 | 100 | 50   | 100 | 50  | 50  | 50  |                                             |
| 10         | 3.12| 6.25| 6.25| 6.25 | 6.25| 6.25| 12.5| 25  |                                             |
| 11         | 25  | 50  | 100 | 100  | 25  | 100 | 25  | 25  |                                             |
| 12         | 50  | 25  | 25  | 50   | 25  | 50  | 25  | 25  |                                             |
| 13         | 25  | 25  | 25  | 50   | 25  | 50  | 50  | 25  |                                             |
| 14         | 50  | 50  | 25  | 50   | 50  | 100 | 25  | 25  |                                             |
| 15         | 25  | 50  | 12.5| 50   | 50  | 100 | 12.5| 25  |                                             |
| 16         | 100 | 50  | 100 | 100  | 100 | 100 | >100| >100|                                             |
| 17         | 50  | 12.5| 12.5| 50   | 12.5| 25  | 50  | 50  |                                             |
| 18         | 50  | 100 | 50  | 100  | 100 | 100 | 12.5| 25  |                                             |
| 19         | 25  | 50  | 25  | 100  | 50  | 25  | 12.5| 12.5|                                             |
| 20         | >100| >100| >100| >100 | >100| >100| >100| >100|                                             |
| 21         | 50  | 25  | 50  | 50   | 50  | 50  | 25  | 6.25|                                             |
| 22         | 50  | 50  | 50  | 50   | 50  | 50  | 25  | 25  |                                             |
| 23         | 50  | 50  | 50  | 50   | 50  | 50  | 50  | 25  |                                             |
| 24         | 100 | 100 | 6.25| 100  | 100 | 12.5| 12.5| 12.5|                                             |
| 25         | 100 | 100 | 50  | 100  | 50  | 100 | 12.5| 25  |                                             |
| 26         | 50  | 50  | 25  | 50   | 50  | 50  | 25  | 25  |                                             |
| 27         | 25  | 25  | 12.5| 50   | 25  | 50  | 6.25| 12.5|                                             |
| 28         | 50  | 50  | 50  | 100  | 50  | 100 | 12.5| 25  |                                             |
| 29         | 25  | 25  | 25  | 100  | 25  | 100 | 25  | 12.5|                                             |
| 30         | 50  | 100 | 50  | 100  | 100 | >100| 25  | 12.5|                                             |
| 31         | >100| >100| >100| >100 | >100| >100| >100| >100|                                             |

*S. a: Staphylococcus aureus, B. s: Bacillus subtilis, E. c: Escherichia coli, P. a: Pseudomonas aeruginosa, S. t: Salmonella typhi, K. P: Klebsiella pneumonia, C. a: Candida albicans, A. n: Aspergillus niger.
*CIP: Ciprofloxacin, *FLU: Fluconazole.
Experiments in duplicates.

### Table 3 HIV-RT inhibitory activity

| Comp. code | % inhibition |
|------------|--------------|
| 4          | 26.2         |
| 5          | 15.7         |
| 6          | 42           |
| 7          | 17.7         |
| 8          | 31           |
| 9          | 27           |
| 10         | 13.8         |
| 11         | 25.8         |
| 12         | 23.5         |
| 13         | 31.8         |
| 14         | 16.2         |
| 15         | 26           |
| 16         | 11           |
| 17         | 23           |
| 18         | 34           |
| 19         | 41.2         |
| 20         | 18.8         |
| 21         | 34           |
| 22         | 24           |
| 23         | 58           |
| 24*        | 73           |
| 25         | 34           |
| 26         | 23           |
| 27         | 34           |
| 28         | 6.5          |
| 29         | 24.5         |
| 30         | 14.1         |
| 31         | 10           |
| Efavirenz*  | 98           |

*IC₅₀ (μM) of compound 24 is 1.31 & efavirenz* 0.0717, concentration used was 1 μM, experiments in duplicates.

### Binding mode analysis

With the aim of rationalizing the biological data obtained and considering the best obtained in vitro results for the compounds 4–31, a molecular modeling study was carried out in order to investigate the possible interactions of the highest active compounds 24, 10 and 4 with the non nucleoside inhibitory binding pocket (NNIBP) of RT, active site of GlcN-6-P synthase and cytochrome P450 14α-sterol demethylase from Candida albicans (Candida P450DM) as the target receptors respectively using the Extra Precision (XP) mode of Glide software [36].

To validate the Glide software, firstly the interaction between TNK651 and HIV-1 RT was modeled. Superimposition of the experimental bound (co-crystallized)
conformation of TNK651 [41] and that predicted by Glide are shown in Figure 2a. Glide successfully reproduced the experimental binding conformations of TNK 651 in the NNRTI-binding pocket of HIV-1 RT with an acceptable root-mean-square deviation (RMSD) of 2.4 Å. Visual inspection was then performed on the resulting docking solutions of the compound 24 to analyze the binding mode and key protein ligand interactions and was compared with that of the experimentally determined binding mode and interactions of the bound ligand TNK651 and the standard efavirenz. The key interactions were mainly hydrogen bonding interactions with Lys103 and Lys101 respectively. The carbonyl oxygen at position 4 in the thiazolidinedione moiety forms a strong H-bond interaction with the NH terminal group of Lys103. Another strong H-bond interaction of the hydroxyl group at the ortho position of the first phenyl ring with one of carbonyl oxygen atoms of Lys101 was observed. The phenyl ring in the 2, 3, 4-trihydroxybenzaldehyde moiety along with the thiazolidinedione moiety was oriented in the bigger hydrophobic pocket formed by Phe227, Pro225, Leu234, Tyr181, Tyr188, Leu100 and Val179 while the CH$_2$CH$_2$CONH linker showed favorable interaction with the amino acid residues Tyr318, Pro236 and Val106. Docking score of the compound 24 (Glide XP score-11.30) was lower than the bound ligand TNK-651 (Glide XP score-13.29) but comparable to that of standard efavirenz (Glide XP score-11.33). Possible interactions for the reference ligand TNK-651, efavirenz and compound 24 have been shown in Figure 2a,b and c respectively.

The active site of GlcN-6-P synthase (PDB code 2VF5) consists of 16 amino acid residues as Glu488, Ser303, Ala602, Ser347, Ser349, Gln348, Thr302, Thr352, Val605, Ala400, Cys300, Val399, Leu601, Leu484, Ser401 and Lys603 as shown in Figure 2d. Figure 2d and f shows the docked poses of the reference ligand and of highest active compound 10 respectively. The binding mode of GlcN-6-P synthase (2VF5) with its bound inhibitor glucosamine-6-Phosphate (Figure 2d) shows 9 hydrogen bonds with residues Glu488, Ser303, Ala602, Ser347, Ser349, Gln384, Thr302, Thr352, hydrophobic interactions with Val605, Ala400, Cys300, Val399, Leu601, Leu484, Ser401 and Lys603 as shown in Figure 2d. Figure 2d and f shows the docked poses of the reference ligand and of highest active compound 10 respectively. The binding mode of GlcN-6-P synthase (2VF5) with its bound inhibitor glucosamine-6-Phosphate (Figure 2d) shows 9 hydrogen bonds with residues Glu488, Ser303, Ala602, Ser347, Ser349, Gln384, Thr302, Thr352, hydrophobic interactions with Val605, Ala400, Cys300, Val399, Leu601, Leu484 and electrostatic interactions with Ser401 and Lys603 with a docking score – 7.16. Docking validation was performed with an RMSD value of 1.674 Å ensuring precision and reproducibility of the docking process (Figure 2e).

To illustrate the binding mode of the newly synthesized compounds in the active site of chimeric 1EA1, the docked pose of the highest active compound 4 (Glide XP score – 8.13) has been analysed as follows (Figure 2g). The key interactions are mainly hydrogen bonding interactions. The hydroxyl group on the benzylidene moiety forms a hydrogen bond with Hie392. The CO in the CH$_2$CH$_2$CONH linker forms a strong coordinate bond with Hem460. The aromatic ring forms π-π stacking interactions with Phe83 residue. The thiazolidinedione ring is oriented in the hydrophobic pocket formed by Tyr181, Phe100, Met255, Val395 and Leu79. Both phenyl rings attached to the thiazolidinedione nucleus makes favorable interactions with the side chains of Leu96, Ala173, Tyr77, Cys394, Phe387, Ile324, Ala389 and Leu321.

These docking results demonstrate that hydrogen bond interactions, hydrophobic interactions and the coordinate bond with the Hem residue in 1EA1 are very important for binding of compound 4 with the active site residues and may be responsible for the very high antifungal activity as shown by compound 4.
Figure 2 2D sketch views. Binding mode of a) Ref. ligand (TNK-651) b) efavirenz c) compound 24 into the NNIBP of 1RT2 d) Glucosamine-6-Phosphate (2VF5) e) Ref ligand fluconazole (chimeric 1EA1) and compounds f) 10 in the active site of 2VF5 g) 4 in the active site of chimeric 1EA1.
Conclusion
In the present study, a series of thiazolidinedione analogs have been synthesized and their structures have been characterized by IR, NMR and mass spectroscopy. All the newly synthesized compounds were tested for HIV-1-RT inhibitory activity by microplate assay method and for antimicrobial activity by two fold serial dilution method. From the modeling studies as well as from the SAR, electronegative groups substituted at various positions of the phenyl rings with a thiazolidinedione scaffold may be responsible for the very high HIV-1-RT inhibitory activity of compound 24. In case of antibacterial activity the methyl groups substituted in the phenyl group attached to the 5th position of the thiazolidinedione ring system plays a significant role while in case of antifungal activity the electronegative groups, particularly hydroxyl groups substituted in the various positions of both the phenyl groups are responsible for enhanced antifungal activity. The study encourages us to consider a new molecular skeleton of thiazolidinediones substituted at the 3rd and 5th position by aryl groups with adequate spacers may be identified as a potential lead compound for the development of anti-HIV agents with the ability to combat opportunistic bacterial and fungal infections.

References
1. Patel D, Kumari P, Patel N. Synthesis of 3-[4-(4-dimethylamino)-6-(4-methyl-2-oxo-2H-chromen-7-yloxy]-1,3,5[triazin-2-ylamino]-phenyl]-2-phenyl-5-(4-pyridin-2-yl-piperazin-1-ylmethyl)-thiazolidine-4-one and their biological evaluation. Med. Chem. Res. 2012;21:10:2926–94.
2. Shiradkar MR, Ghodale MK, Bothara KG, Bhardaul SB, Nikalje A, Akula KC, et al. Synthesis and anticonvulsant activity of double thiazolidinedione-barbituric acid and thiazolidinedione-thioarbazone derivatives. ARKIVOC. 2007;XXV:58.
3. Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, et al. Novel euglycemic and hypolipidemic agents. J. Med. Chem. 1998;41:1619–30.
4. Prabhakar C, Madhusudhan G, Sahadev K, Mahendradha Reddy C, Sama M, Reddy GO, et al. Synthesis and biological activity of novel thiazolidinediones. Bioorg Med Chem Lett. 1999;8:2725–30.
5. Sundarau N, Srivastava K, Rajakumar S, Puri S, Saxena J, Chauhan P. Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials. Bioorg Med Chem Lett. 2009;19:2570–3.
6. Reddy KA, Lohray B, Bhushan V, Reddy AS, Kishore PH, Rao W, et al. Novel euglycemic and hypolipidemic agents Part-2 antioxidant moiety as structural motif. Bioorg Med Chem Lett. 1998;8:999–1002.
7. Hafez HN, El-Gazzar A-R. Synthesis and antitumor activity of substituted triazole [4, 3-a] pyrimidin-6-sulfonamide with an incorporated thiazolidinedione moiety. Bioorg Med Chem Lett. 2009;19:14143–7.
8. Patil V, Tilleker K, Mehendale-Munj S, Mohan R, Ramaa C. Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Eur J Med Chem. 2010;45:6358–44.
9. Borde CG, Gaikward NJ. Synthesis and preliminary evaluation of some pyrazine containing thiazolines and thiazolidiones as antimicrobial agents. Bioorg Med Chem. 2004;12:2151–61.
10. Ahamathu N, Guo Y, Harbincki F, Fan YH, Chen H, Luus L, et al. Novel arylsulfonilamide-oxindole hybrids as an antitumor agent that inhibits translation initiation. J Med Chem. 2004;47(21):9779–82.
11. Tomasic T, Zidar N, Mueller-Premru M, Kilej D, Masic LP. Synthesis and antibacterial activity of 5′-yldentehazolidin-4-ones and 5-benzylidene-4,6-pyrimidinediones. Eur J Med Chem. 2010;45(4):1667–72.
12. Carroll RT, Dzielen DE, Stinnett H, Awale PS, Funk MO, Goldenhuyss WJ. Structure–activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B. Bioorg Med Chem Lett. 2011;21:4798–803.
13. Youssef AM, Sydney White M, Villarueua EB, El-Ashmawy IM, Kliegeris A. Synthesis and biological evaluation of novel pyrazolyld-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorg Med Chem. 2010;18:2019–28.
14. Ali AM, Saber GE, Mahfouz NW, El-Gendi MA, Rodwan AA, Hamida MA. Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinediones derivatives as COX inhibitors. Arch Pharm Res. 2007;30:1186–204.
15. Malik S, Choudhary A, Bahare RS. Synthesis of some novel substituted arylidene and substituted benzylthiazolidine-2,4-diones analogues as chemotherapeutic agents. Asian J Chem. 2011;23:5547–8.
16. Barica ML, Balzarni J, Chimnri A, Clercq ED, Luca LD, Holllje HD, et al. Design, Synthesis, Structure Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolinedione-4-ones as Potent Anti-HIV Agents. J Med Chem. 2002;45(24):5140–3.
17. Zhang GH, Wang Q, Chen JJ, Zhang XM, Tan SC, Zheng YT, et al. The anti-HIV-1 effect of scutellarin. Bochim Biophs Res Commun. 2005;334:812–6.
18. Srimat D, Bal TR, Yogeeswari P. Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Bioorg Med Chem. 2004;12(22):5865–73.
19. Ganguly S, Murugesan S, Prasanthi N, Alptürk O, Herman B, Cremer NS. Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminooimidazole Analogos. Lett Drug Des Discov. 2010;7(5):318–23.
20. Dundar B, Dezen OB, Menteşe A, Altınar N, Altı N, Kendi E, et al. Synthesis and anticonvulsant activity of some thiazolyl thiazolidine-2,4-dione derivatives. Bioorg Med Chem. 2007;15(18):6012–8.
21. Chopra I, Schofield C, Everett M, Neill AO, Miller K, Wilcox M, et al. Treatment of health-care- associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis. 2008;8(2):133–9.
22. Beale JM, Block J. Organic Medicinal & Pharmaceutical Chemistry. Philadelphia: Lippincott Williams & Wilkins; 2010.
23. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial blood stream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29(2):239–44.

24. Vjesh AM, Isloor AM, Telkar S, Fun HK. Molecular docking studies of some new imidazole derivatives for antimicrobial properties. Arabian J Chem. 2013;6:197–204.

25. Chmara H, Andruszewicz R, Borowski E. Inactivation of glucosamine-6-phosphatesynthetase from Salmonella typhimurium LT2 SL 1027 by N-beta-fumarylcarboxyamido-l-2,3-diamino-propionic acid. Biochem Biophys Res Commun. 1984;120:865–72.

26. Sangamwar AT, Deshpande UD, Pekamwar SS. Antifungals: need to search for a new molecular target. Indian J Pharm Sci. 2008;70(4):423–30.

27. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996;40(2):279.

28. Perfect JR. Molecular targets for new antifungal drugs. Can J Bot. 1995;73(5):1187–91.

29. Groll AH, De Luca AJ, Walsh TJ. Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol. 1998;6(3):117–24.

30. Sangshetti JN, Lokwani DK, Sarkate SP, Shinde DB. Synthesis, Antifungal Activity, and Docking Study of Some New 1, 2, 4-triazole Analogs. Chem Biol Drug Des. 2011;78(5):800–9.

31. Prakash O, Aneja DK, Sharma C, Aneja KR. Synthesis and antimicrobial activities of some new 5-(3-aryl-phenyl-1H-pyrazol-4-yl)methylene-3-phenylthiazolidin-2,4-diones. Med Chem Res. 2012;21:10–5.

32. Ganguly S, Bahare RS. Molecular docking studies of novel thiazolidinedione analogs as HIV-1-RT inhibitors. Med Chem Res. 2013;22(7):3350–63.

33. Sachan N, Kadam SS, Kulkarni VM. Synthesis and antihyperglycemic activity and QSAR of 5-benzyline2A-thiazolidinediones. Indian J Heterocycl Chem. 2007;57.

34. NCCLS. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7: A5. Villanova, PA: NCCLS; 2000.

35. Silprasit K, Thammaporn R, Tecsahasakul S, Hannonphu S, Choowongkamon K. Simple and rapid determination of the enzyme kinetics of HIV-1 reverse transcriptase and anti-HIV-1 agents by a fluorescence based method. J Virol Methods. 2011;177:381–7.

36. Glide 5.0, Schr"{o}dinger, Inc. New York, U.S.A; 2008, www.schrodinger.com.

37. Ganguly S, Bahare RS. Comparative molecular docking studies of novel 3, 5-disubstituted. Med Chem Res. 2014;23:1300–8.

38. Podust LM, Stojan J, Poulos TL, Waterman MR. Substrate recognition sites in 14α-sterol Demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. Proc Natl Acad Sci U S A. 2001;98:3069–73.

39. Podust LM, Stojan J, Poulos TL, Waterman MR, Stojan J, Poulos TL, et al. Substrate recognition sites in 14α-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J Inorg Biochem. 2001;87(4):227–35.

40. Morugesan S, Ganguly S, Maga G. Synthesis, evaluation and molecular modelling studies of some novel 3-(3, 4-dihydroisoquinolin-2(1H)-yl-N-(substitutedphenyl) propanamides as HIV-1 non-nucleoside reverse transcriptase inhibitors. J Chem Sci. 2010;122:169–76.

41. Hopkins AL, Rein J, Esnouf RM, Willcox BE, Jones EY, Ross C, et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem. 1996;39(8):1600–1603.